Fluorinov Pharma
2008
FOUNDED
M&A
STATUS
M&A
LATEST DEAL TYPE
$31.7M
LATEST DEAL AMOUNT
1
INVESTORS
Description
Operator of a pharmaceutical company intended to develop fluorine-based novel, safer and more effective medicine. The company's services include developing small molecule product portfolio for Multiple Myeloma, Waldenström's Macroglobulinemia, Leukemia, Glioblastoma, Lung and Pancreatic Cancers and Central Nervous System disorders, enabling patients to avail therapeutics to treat and avoid cancer diseases.
Website
Ownership Status
Acquired/Merged
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Drug Delivery
Acquirer
Primary Office
- MaRS Centre, South Tower
- 101 College Street, Suite 300, L-349
- Toronto, Ontario M5G 1L7
- Canada
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Fluorinov Pharma’s full profile, request a free trial.
Fluorinov Pharma Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 27-Jan-2016 | $31.7M | 000.00 | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 01-Jan-2010 | Completed | Generating Revenue |